US Patent Reform Legislation Threatened By Biden Support For Vaccine IP Waiver, Republicans Say
Executive Summary
At hearing on Humira patent thicket, House Republicans express concern that Democrats’ support for transferring US intellectual property rights for COVID-19 vaccines to other countries is a bad sign for collaboration on legislation to reform patent abuses.
You may also be interested in...
FDA, USPTO In Middle Of Congressional Tug-Of-War Over Patents And Drug Pricing
Senators Hassan and Cassidy contend the lack of coordination between the two agencies may allow patent thickets to grow. Meanwhile, Sen. Tillis is pushing the agency to refute data alleging patents are to blame for high drug prices.
USPTO Faces Growing Pressure To Enter Battle Over Drug Pricing
Members of Congress, companies and government agencies want the Patent Office to change policies that they say impede generic drug competition. The latest effort is focused on PTO’s discretionary denial of inter partes review petitions, which is the subject of a bipartisan congressional letter and cert petition to the US Supreme Court.
From Pricing To Tax Havens: AbbVie On The Hot Seat Again With US Congress
Senate committee seeks details on company’s international tax practices as congress works to implement President Biden’s proposals on corporate tax reform.